Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...
Genmab drops as Bernstein cuts on Darzalex patent cliff
Genmab (GMAB) stock was downgraded by Bernstein due to a looming patent cliff for Darzalex, a blood cancer drug marketed by ...
Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?
We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...
3BNTX : BioNTech Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...
Genmab A/S (0MGB) was downgraded to a Sell Rating at Bernstein
Bernstein analyst Justin Smith downgraded Genmab A/S (0MGB – Research Report) to a Sell on March 28 and set a price target of DKK1,000.00. The ...
Genmab downgraded by Bernstein amid Darzalex concerns
Investing.com -- Bernstein analysts have downgraded Genmab A/S (CSE: GMAB) to an "underperform" rating from "market perform,” in a note dated Tuesday. Shares of the Danish biotechnology company were ...
Genmab downgraded to Underperform from Market Perform at Bernstein
Bernstein downgraded Genmab (GMAB) to Underperform from Market Perform with a price target of DKK 1,000, down from DKK 1,580. The share price ...
Le Lézard1d
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...
The Pharma Letter5d
Genmab’s Tivdak approved in Japan
Danish cancer specialist Genmab today announced that the Japanese Ministry of Health, Labor and Welfare has approved Tivdak ...
American Association of Individual Investors5d
3 Undervalued Biotechnology Stocks for Thursday, March 27
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued ...
Truist Financial Reaffirms Their Buy Rating on Exelixis (EXEL)
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Exelixis (EXEL – Research Report). The company’s shares closed yesterday at $ ...
Genmab A/S (NASDAQ:GMAB) Holdings Decreased by Envestnet Portfolio Solutions Inc.
Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the ...